https://orcid.org/0000-0002-8744-2535
Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nicola Principi, Giovanni Autore, Serafina Perrone & Susanna Esposito. (2023) Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants. Expert Opinion on Pharmacotherapy 24:6, pages 747-762.
Read now
Read now
Nusrat Zahan Rouf, Sumit Biswas, Nawseen Tarannum, Labiba Mustabina Oishee & Mutia Masuka Muna. (2022) Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biology 19:1, pages 386-410.
Read now
Read now
Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, Jon H. Heinrichs, Paolo Manzoni, Matteo Riccò, Michelle Roberts & Natalya Vassilouthis. (2022) RSV disease in infants and young children: Can we see a brighter future?. Human Vaccines & Immunotherapeutics 18:4.
Read now
Read now
J.A Soto, N.M.S Galvez, D.B Rivera, F.E Díaz, C.A Riedel, S.M Bueno & A.M Kalergis. (2022) From animal studies into clinical trials: the relevance of animal models to develop vaccines and therapies to reduce disease severity and prevent hRSV infection. Expert Opinion on Drug Discovery 17:11, pages 1237-1259.
Read now
Read now
Dengyun Sun, Ying X Homan, Joseph M Antonello, Danila Giacone, Leah Bogardus, Yuhua Zhang, Wen Feng, Ivette C Caro-Aguilar, Amy Hsu, Shara Dellatore & Melissa C Whiteman. (2022) Virus Reduction Neutralization Test and LI-COR Microneutralization Assay Bridging and WHO International Standard Calibration Studies for Respiratory Syncytial Virus. Bioanalysis 14:15, pages 1067-1079.
Read now
Read now
Nitika, Jiao Wei & Ai-Min Hui. (2021) The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. Infection and Drug Resistance 14, pages 5271-5285.
Read now
Read now
Articles from other publishers (70)
Nuttapat Pisuttinusart, Balamurugan Shanmugaraj, Chanya Srisaowakarn, Chutitorn Ketloy, Eakachai Prompetchara, Arunee Thitithanyanont & Waranyoo Phoolcharoen. (2024) Immunogenicity of a recombinant plant-produced respiratory syncytial virus F subunit vaccine in mice. Biotechnology Reports 41, pages e00826.
Crossref
Crossref
Jin Kyun Park, Eun Bong Lee & Kevin L Winthrop. (2024) What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, pages ard-2024-225492.
Crossref
Crossref
Xinyu Zhang, Yuanfang Li & Zehua Zhou. (2024) Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA Vaccines. ACS Omega 9:6, pages 6219-6234.
Crossref
Crossref
Huajun Zhao, Xianyu Shao, Yating Yu, Lulu Huang, Narh Philip Amor, Kun Guo, Changzhen Weng, Weijun Zhao, Ailu Yang, Jiesen Hu, Hongbao Yang, Zhenguang Liu, Qiuju Han, Leilei Shi, Shiyu Sun, Jian Zhang, Ang Lin & Yong Yang. (2024) A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. npj Vaccines 9:1.
Crossref
Crossref
Yichao Lu, Xu Liu & Jian You. (2024) Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity. Nano Today 54, pages 102129.
Crossref
Crossref
Piotr Rzymski & Willis Gwenzi. (2024) Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity. Journal of Medical Virology 96:2.
Crossref
Crossref
Christine A Shaw, Runa Mithani, Archana Kapoor, Rakesh Dhar, Lauren Wilson, Laila El Asmar, Sabine Schnyder-Ghamloush, Kristi Schaefers, Allison August, Sonia K Stoszek & Grace L Chen. (2024) Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial. The Journal of Infectious Diseases.
Crossref
Crossref
Puthupparampil V. Scaria, Nicole Roth, Kim Schwendt, Olga V. Muratova, Nada Alani, Lynn E. Lambert, Emma K. Barnafo, Christopher G. Rowe, Irfan U. Zaidi, Kelly M. Rausch, David L. Narum, Benjamin Petsch & Patrick E. Duffy. (2024) mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response. npj Vaccines 9:1.
Crossref
Crossref
Huyen Trang Ha Thi & Van Thai Than. 2024. RNA Therapeutics Part A. RNA Therapeutics Part A
115
150
.
Marli Azevedo & Anil K. Patri. 2024. Comprehensive Precision Medicine. Comprehensive Precision Medicine
304
321
.
Sandro Roier, Vidya Mangala Prasad, Monica M. McNeal, Kelly K. Lee, Benjamin Petsch & Susanne Rauch. (2023) mRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents. npj Vaccines 8:1.
Crossref
Crossref
Wanbo Tai, Kai Yang, Yubin Liu, Ruofan Li, Shengyong Feng, Benjie Chai, Xinyu Zhuang, Shaolong Qi, Huicheng Shi, Zhida Liu, Jiaqi Lei, Enhao Ma, Weixiao Wang, Chongyu Tian, Ting Le, Jinyong Wang, Yunfeng Chen, Mingyao Tian, Ye Xiang, Guocan Yu & Gong Cheng. (2023) A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection. Nature Communications 14:1.
Crossref
Crossref
Kay Choong See. (2023) Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians. Vaccines 11:12, pages 1809.
Crossref
Crossref
Changxu Chen, Xin Wang & Zeli Zhang. (2023) Humoral and cellular immunity against diverse SARS-CoV-2 variants. Journal of Genetics and Genomics 50:12, pages 934-947.
Crossref
Crossref
Allen Y. Jiang, Jacob Witten, Idris O. Raji, Feyisayo Eweje, Corina MacIsaac, Sabrina Meng, Favour A. Oladimeji, Yizong Hu, Rajith S. Manan, Robert Langer & Daniel G. Anderson. (2023) Combinatorial development of nebulized mRNA delivery formulations for the lungs. Nature Nanotechnology.
Crossref
Crossref
Winthrop KL. (2023) mRNA vaccines in the rheumatologist's future. Seminars in Arthritis and Rheumatism, pages 152325.
Crossref
Crossref
Jennifer A. Whitaker, Hana M. El Sahly & C. Mary Healy. (2023) mRNA vaccines against respiratory viruses. Current Opinion in Infectious Diseases 36:5, pages 385-393.
Crossref
Crossref
Jesse Nussbaum, Xin Cao, Radha A. Railkar, Jeffrey R. Sachs, Daniel S. Spellman, Julie Luk, Christine A. Shaw, Pedro J. Cejas, Michael P. Citron, Mohamed Al-Ibrahim, David Han, Sandra Pagnussat, S. Aubrey Stoch, Eseng Lai, Andrew J. Bett & Amy S. Espeseth. (2023) Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine 41:44, pages 6488-6501.
Crossref
Crossref
Li Ou, Steven J. Chen, I-Ting Teng, Lijuan Yang, Baoshan Zhang, Tongqing Zhou, Andrea Biju, Cheng Cheng, Wing-Pui Kong, Nicholas C. Morano, Erik-Stephane D. Stancofski, John-Paul Todd, Yaroslav Tsybovsky, Shuishu Wang, Cheng-Yan Zheng, John R. Mascola, Lawrence Shapiro, Ruth A. Woodward, Ursula J. Buchholz & Peter D. Kwong. (2023) Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus. PLOS Pathogens 19:9, pages e1011584.
Crossref
Crossref
Gang Zhang, Tianyu Tang, Yinfeng Chen, Xing Huang & Tingbo Liang. (2023) mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Calvin Yee Fen Lee, Salman J Khan, Fnu Vishal, Sadaf Alam & Syeda Fatima Murtaza. (2023) Respiratory Syncytial Virus Prevention: A New Era of Vaccines. Cureus.
Crossref
Crossref
Londiwe Simphiwe Mbatha, Jude Akinyelu, Fiona Maiyo & Tukayi Kudanga. (2023) Future prospects in mRNA vaccine development. Biomedical Materials 18:5, pages 052006.
Crossref
Crossref
Hualin Helen Li, Jenny Xu, Li He, Lynne Ireland Denny, Richard R. Rustandi, Geethanjali Dornadula, Brock Fiorito & Zhi-Qiang Zhang. (2023) Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine. Journal of Pharmaceutical and Biomedical Analysis 234, pages 115523.
Crossref
Crossref
Zhe Wang, Wanting Ma, Xingxing Fu, Yanfei Qi, Yinan Zhao & Shubiao Zhang. (2023) Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnology Advances 65, pages 108130.
Crossref
Crossref
Yukai Huang, Xuerui Zhu, Xiao Guo, Yuancheng Zhou, Dongying Liu, Jingrui Mao, Yongai Xiong, Youcai Deng & Xinghong Gao. (2023) Advances in mRNA vaccines for viral diseases. Journal of Medical Virology 95:7.
Crossref
Crossref
Christine A. Shaw, Allison August, Stephan Bart, Peta-Gay Jackson Booth, Conor Knightly, Trevor Brasel, Scott C. Weaver, HongHong Zhou & Lori Panther. (2023) A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine 41:26, pages 3898-3906.
Crossref
Crossref
Mena Hajiaghapour Asr, Fatemeh Dayani, Fatemeh Saedi Segherloo, Ali Kamedi, Andrew O’ Neill, Ronan MacLoughlin & Mohammad Doroudian. (2023) Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections. Pharmaceutics 15:4, pages 1127.
Crossref
Crossref
Jordi Reina & Elisa Gónzalez de Herrero. (2023) Current situation and future perspectives of vaccines against respiratory syncytial virus. Vacunas (English Edition) 24:2, pages 150-157.
Crossref
Crossref
Jordi Reina & Elisa Gónzalez de Herrero. (2023) Situación actual y perspectivas de futuro de las vacunas frente al virus respiratorio sincitial. Vacunas 24:2, pages 150-157.
Crossref
Crossref
Piotr Rzymski, Agnieszka Szuster‐Ciesielska, Tomasz Dzieciątkowski, Willis Gwenzi & Andrzej Fal. (2023) mRNA vaccines: The future of prevention of viral infections?. Journal of Medical Virology 95:2.
Crossref
Crossref
Dvir Gatt, Isaac Martin, Rawan AlFouzan & Theo J. Moraes. (2023) Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens 12:2, pages 154.
Crossref
Crossref
Ki Wook Yun. (2023) Recent Advances in the Prevention of RSV in Neonates and Young Infants. Pediatric Infection & Vaccine 30:1, pages 1.
Crossref
Crossref
JiaYan FU, Shuo FENG, BinHe DU, HaiYang DONG, JinZhong LIN & YongFeng JIN. (2022) mRNA疗法的研究进展与挑战. SCIENTIA SINICA Vitae 53:1, pages 30-49.
Crossref
Crossref
David B. Weiner, Kathrin Jansen & Tonya Villafana. 2023. Plotkin's Vaccines. Plotkin's Vaccines
1374
1396.e11
.
Svenja M. Sake, Christina Kosch, Sebastian Blockus, Sibylle Haid, Antonia P. Gunesch, Xiaoyu Zhang, Martina Friesland, Sofie B. Trummer, Christina Grethe, Anne Kühnel, Jessica Rückert, W. Paul Duprex, Jiabin Huang, Marie-Anne Rameix-Welti, Martin Empting, Nicole Fischer, Anna K. H. Hirsch, Thomas F. Schulz & Thomas Pietschmann. (2022) Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages. Antimicrobial Agents and Chemotherapy 66:12.
Crossref
Crossref
Camila Montesinos-Guevara, Diana Buitrago-Garcia, Maria L Felix, Claudia V Guerra, Ricardo Hidalgo, Maria José Martinez-Zapata & Daniel Simancas-Racines. (2022) Vaccines for the common cold. Cochrane Database of Systematic Reviews 2022:12.
Crossref
Crossref
Thomas J. Powell, Andrea Jacobs, Jie Tang, Edwin Cardenas, Naveen Palath, Jennifer Daniels, James G. Boyd, Harrison C. Bergeron, Patricia A. Jorquera & Ralph A. Tripp. (2022) Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge. Vaccines 10:12, pages 2078.
Crossref
Crossref
Xirui Qiu, Siyan Xu, Yang Lu, Zichen Luo, Yangtian Yan, Chuyue Wang & Jianjian Ji. (2022) Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine & Growth Factor Reviews 68, pages 37-53.
Crossref
Crossref
Kelsey A. Brakel, Yuanmei Ma, Rashmi Binjawadagi, Olivia Harder, Mauria Watts, Jianrong Li, Basavaraj Binjawadagi & Stefan Niewiesk. (2022) Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model. Virology 575, pages 101-110.
Crossref
Crossref
Min Lin, Wei Zhang, Yi-Fan Yin, Jun-Yu Si, Lu-Jing Zhang, Li Chen, Xue Lin, Ying-Bin Wang, Jun Zhang, Zi-Zheng Zheng & Ning-Shao Xia. (2022) An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease. Viruses 14:10, pages 2085.
Crossref
Crossref
Jordi Reina & María Fernández-Billón. (2022) Preliminary data on messenger RNA (mRNA) vaccines against respiratory syncytial virus. Vacunas (English Edition) 23:3, pages 215-221.
Crossref
Crossref
Jordi Reina & María Fernández-Billón. (2022) Datos preliminares de las vacunas de ARN mensajero (ARNm) frente al virus respiratorio sincitial. Vacunas 23:3, pages 215-221.
Crossref
Crossref
Tao Huang, Lushan Peng, Yingying Han, Dan Wang, Xiaoyun He, Junpu Wang & Chunlin Ou. (2022) Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Frontiers in Immunology 13.
Crossref
Crossref
Takehiro Ura, Masaki Takeuchi, Tatsukata Kawagoe, Nobuhisa Mizuki, Kenji Okuda & Masaru Shimada. (2022) Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines 10:8, pages 1367.
Crossref
Crossref
Jessica A. Flynn, Teresa Weber, Pedro J. Cejas, Kara S. Cox, Sinoeun Touch, Lauren A. Austin, Yangsi Ou, Michael P. Citron, Bin Luo, Marian E. Gindy, Kapil Bahl, Giuseppe Ciaramella, Amy S. Espeseth & Lan Zhang. (2022) Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates. Vaccine 40:32, pages 4412-4423.
Crossref
Crossref
Mia Karam & Georges Daoud. (2022) mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences 17:4, pages 491-522.
Crossref
Crossref
Emily Phung, Lauren A. Chang, Maryam Mukhamedova, Lijuan Yang, Deepika NairScott A. Rush, Kaitlyn M. Morabito, Jason S. McLellan, Ursula J. BuchholzJohn R. Mascola, Michelle C. Crank, Grace ChenBarney S. Graham & Tracy J. Ruckwardt. (2022) Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine 14:650.
Crossref
Crossref
Ann R Falsey, Edward E Walsh, Daniel A Scott, Alejandra Gurtman, Agnieszka Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, Qin Jiang, Emily Gomme, David Cooper & Beate Schmoele-Thoma. (2022) Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. The Journal of Infectious Diseases 225:12, pages 2056-2066.
Crossref
Crossref
Ann J. Barbier, Allen Yujie Jiang, Peng Zhang, Richard Wooster & Daniel G. Anderson. (2022) The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology 40:6, pages 840-854.
Crossref
Crossref
Wei Wang, Shuo Feng, Zhuyifan Ye, Hanlu Gao, Jinzhong Lin & Defang Ouyang. (2022) Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. Acta Pharmaceutica Sinica B 12:6, pages 2950-2962.
Crossref
Crossref
Shugang Qin, Xiaoshan Tang, Yuting Chen, Kepan Chen, Na Fan, Wen Xiao, Qian Zheng, Guohong Li, Yuqing Teng, Min Wu & Xiangrong Song. (2022) mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Abid Hussain, Haiyin Yang, Mengjie Zhang, Qing Liu, Ghallab Alotaibi, Muhammad Irfan, Huining He, Jin Chang, Xing-Jie Liang, Yuhua Weng & Yuanyu Huang. (2022) mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release 345, pages 314-333.
Crossref
Crossref
Caleb Kinsey, Tian Lu, Alyssa Deiss, Kim Vuolo, Lee Klein, Richard R. Rustandi & John W. Loughney. (2021) Determination of lipid content and stability in lipid nanoparticles using ultra high‐performance liquid chromatography in combination with a Corona Charged Aerosol Detector. ELECTROPHORESIS 43:9-10, pages 1091-1100.
Crossref
Crossref
Yong-Qiang Deng, Na-Na Zhang, Yi-Fei Zhang, Xia Zhong, Sue Xu, Hong-Ying Qiu, Tie-Cheng Wang, Hui Zhao, Chao Zhou, Shu-Long Zu, Qi Chen, Tian-Shu Cao, Qing Ye, Hang Chi, Xiang-Hui Duan, Dan-Dan Lin, Xiao-Jing Zhang, Liang-Zhi Xie, Yu-Wei Gao, Bo Ying & Cheng-Feng Qin. (2022) Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Research 32:4, pages 375-382.
Crossref
Crossref
Enyue Fang, Xiaohui Liu, Miao Li, Zelun Zhang, Lifang Song, Baiyu Zhu, Xiaohong Wu, Jingjing Liu, Danhua Zhao & Yuhua Li. (2022) Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Hannah Zogg, Rajan Singh & Seungil Ro. (2022) Current Advances in RNA Therapeutics for Human Diseases. International Journal of Molecular Sciences 23:5, pages 2736.
Crossref
Crossref
Yingqi Jin, Chen Hou, Yonghao Li, Kang Zheng & Chuan Wang. (2022) mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. Frontiers in Immunology 12.
Crossref
Crossref
Tomer Zohar, Jeff C. Hsiao, Nickita Mehta, Jishnu Das, Anush Devadhasan, Wiktor Karpinski, Cheryl Callahan, Michael P. Citron, Daniel J. DiStefano, Sinoeun Touch, Zhiyun Wen, Jeffrey R. Sachs, Pedro J. Cejas, Amy S. Espeseth, Douglas A. Lauffenburger, Andrew J. Bett & Galit Alter. (2022) Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host & Microbe 30:1, pages 41-52.e5.
Crossref
Crossref
Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Marina Beraza-Millor, Alicia Rodríguez-Gascón, Ana del Pozo-Rodríguez & María Ángeles Solinís. 2022. mRNA-Based Therapeutics. mRNA-Based Therapeutics
207
293
.
Yingshan Qiu, Michael Yee-Tak Chow & Jenny Ka-Wing Lam. 2022. Messenger RNA Therapeutics. Messenger RNA Therapeutics
139
156
.
Allison August, Husain Z. Attarwala, Sunny Himansu, Shiva Kalidindi, Sophia Lu, Rolando Pajon, Shu Han, Jean-Michel Lecerf, Joanne E. Tomassini, Marjie Hard, Leon M. Ptaszek, James E. Crowe & Tal Zaks. (2021) A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nature Medicine 27:12, pages 2224-2233.
Crossref
Crossref
Rebecca Glowinski, Asuncion Mejias & Octavio Ramilo. (2021) New preventive strategies for respiratory syncytial virus infection in children. Current Opinion in Virology 51, pages 216-223.
Crossref
Crossref
A. V. Blagov, A. A. Bukaeva, V. V. Makarov & Z. V. Bochkaeva. (2021) Safety and efficacy of RNA vaccines: State of the art. Medical Immunology (Russia) 23:5, pages 1017-1030.
Crossref
Crossref
Namit Chaudhary, Drew Weissman & Kathryn A. Whitehead. (2021) mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery 20:11, pages 817-838.
Crossref
Crossref
Caroline Chupin, Andrés Pizzorno, Aurélien Traversier, Pauline Brun, Daniela Ogonczyk-Makowska, Blandine Padey, Cédrine Milesi, Victoria Dulière, Emilie Laurent, Thomas Julien, Marie Galloux, Bruno Lina, Jean-François Eléouët, Karen Moreau, Marie-Eve Hamelin, Olivier Terrier, Guy Boivin, Julia Dubois & Manuel Rosa-Calatrava. (2021) Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®. Vaccines 9:10, pages 1190.
Crossref
Crossref
Michelle Meyer, Yuan Wang, Darin Edwards, Gregory R. Smith, Aliza B. Rubenstein, Palaniappan Ramanathan, Chad E. Mire, Colette Pietzsch, Xi Chen, Yongchao Ge, Wan Sze Cheng, Carole Henry, Angela Woods, LingZhi Ma, Guillaume B.E. Stewart-Jones, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Sivakumar Periasamy, Pei-Yong Shi, Barney S. Graham, Ian N. Moore, Irene Ramos, Olga G. Troyanskaya, Elena Zaslavsky, Andrea Carfi, Stuart C. Sealfon & Alexander Bukreyev. (2021) Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation 131:20.
Crossref
Crossref
Emily H. Pilkington, Estelle J.A. Suys, Natalie L. Trevaskis, Adam K. Wheatley, Danijela Zukancic, Azizah Algarni, Hareth Al-Wassiti, Thomas P. Davis, Colin W. Pouton, Stephen J. Kent & Nghia P. Truong. (2021) From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia 131, pages 16-40.
Crossref
Crossref
Subbiah Jeeva, Ki-Hye Kim, Chong Hyun Shin, Bao-Zhong Wang & Sang-Moo Kang. (2021) An Update on mRNA-Based Viral Vaccines. Vaccines 9:9, pages 965.
Crossref
Crossref
Jing Shan, Philip N. Britton, Catherine L. King & Robert Booy. (2021) The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. Influenza and Other Respiratory Viruses 15:4, pages 539-551.
Crossref
Crossref
Laura M. Stephens & Steven M. Varga. (2021) Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines 9:6, pages 624.
Crossref
Crossref